Colimex

Quick links to important sections

Colimex

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colimex

What is Colimex?

Colimex is a combination medication typically used to manage symptoms associated with gastrointestinal discomfort and spasms. It is formulated as a fixed-dose combination containing two active pharmacological agents: dicyclomine hydrochloride and paracetamol (also known as acetaminophen).

Composition and Mechanisms

The effectiveness of Colimex is derived from the synergistic action of its two primary components:

  • Dicyclomine Hydrochloride: This component belongs to a class of medications known as antispasmodics or anticholinergics. It works by relaxing the smooth muscles of the stomach and intestines. By inhibiting the action of acetylcholine at specific receptor sites, it helps to relieve muscle spasms and cramps in the digestive tract.
  • Paracetamol: This is a widely used analgesic (pain reliever) and antipyretic (fever reducer). In the context of this combination, it acts centrally to increase the pain threshold, helping to alleviate the discomfort associated with abdominal cramping.

Clinical Applications

Colimex is primarily utilized to provide relief from symptoms involving the digestive system. Its clinical use is often focused on conditions characterized by smooth muscle hyperactivity, such as:

  • Abdominal Colic: Sharp, localized pain often caused by spasms in the hollow organs of the abdomen.
  • Irritable Bowel Syndrome (IBS): Managing the periodic cramping and functional discomfort associated with this chronic condition.
  • Biliary or Renal Colic: Supportive relief for intense pain resulting from contractions in the bile ducts or urinary tract.
  • Spastic Constipation: Relief of discomfort when bowel movements are difficult due to intestinal spasms.

By addressing both the physical muscle contraction and the perception of pain, the medication aims to restore comfort and improve functional movement within the gastrointestinal system.

What side effects are possible with Colimex?

Possible side effects and safety information

The safety characteristics of Colistimethate Sodium (Colimex) are officially structured around two primary types of systemic toxicity: effects on the kidneys (Nephrotoxicity) and effects on the nervous system (Neurotoxicity). These are consistently documented across regulatory labels as the principal adverse reaction concerns.


Adverse Reactions and Systemic Classification

Official prescribing information classifies adverse effects by body system and frequency. Reactions classified as Common following parenteral (injection) administration include Paresthesia (tingling or numbness) and Dizziness. For inhaled use, Unpleasant taste, Cough, and Throat irritation are often classified as Very Common.

Key system-organ classes involved include Renal and Urinary Disorders, which encompass the risk of Acute Renal Failure, and Nervous System Disorders, which include disturbances such as Slurred speech, Vertigo, and potentially Seizures.

Serious and Exposure-Related Safety

The most serious adverse reactions documented in regulatory sources are those related to systemic failure, including Acute Renal Insufficiency and Respiratory Arrest resulting from neuromuscular blockade. The risk of Nephrotoxicity is officially stated to be associated with both the cumulative dose and the duration of treatment.

Population-Specific Safety Notes

Safety constraints are explicitly defined for specific populations. Patients with pre-existing Renal Impairment are at a significantly increased risk of toxic reactions. Furthermore, the label contraindicates use in individuals with Myasthenia Gravis due to the heightened risk of respiratory arrest. Caution is also advised when considering use in Older Adults and during Pregnancy due to the potential for increased toxicity and transfer across the placental barrier, respectively.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Colistimethate Sodium is documented in official regulatory labeling to present primarily across two major toxicological domains. The potential for the administered amount to exceed the body's renal excretory capacity is a critical factor leading to high serum levels and systemic toxicity. This situation mandates seeking immediate medical help.

Documented manifestations include severe neurological disturbances and signs of organ impairment. Neurological symptoms may involve generalized muscular weakness, dizziness, ataxia (loss of coordination), and speech disturbances. Signs of renal impairment include laboratory findings such as elevated BUN and diminished urine output (oliguria or anuria).

The most severe outcomes noted in official labeling are the life-threatening risks of acute renal insufficiency, potential renal shutdown, and apnea (respiratory arrest) resulting from interference of nerve transmission at the neuromuscular junction. Due to these critical risks, regulators mandate that a suspected overdose requires contacting a Poison Control Centre immediately and seeking urgent medical attention.

Management is defined as symptomatic and supportive treatment, noting that no specific antidote is known. In cases of massive overdosage, consideration of dialysis is officially described. Individuals with impaired renal function, as well as infants and young children, are noted as populations requiring close monitoring due to increased overdose risk.

Therapeutic Uses of Colimex

Colimex is used across therapeutic domains where supportive symptomatic management is needed for infections caused by multi-drug resistant (MDR) bacteria. The medication is generally used to help treat certain bacterial infections in situations where other therapeutic options are limited.


Addressing Multi-Drug Resistant Infections in Acute Clinical Contexts

This therapeutic domain is applied in critical care settings for patients with severe, acute conditions presenting with systemic or localized discomfort. It is used in conditions like sepsis, bacteremia (bloodstream infections), and severe pneumonias, and is considered relevant in situations involving inflammatory or irritative processes where the infectious agent has shown resistance to multiple other therapeutic options. The medication is commonly used to help with infections caused by certain MDR Gram-negative organisms, including Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. The primary therapeutic benefit is offering a salvage treatment option that may assist with addressing the underlying infection, which helps to ease symptoms related to systemic imbalance caused by the infection.

“Applied in clinical settings that involve acute or unstable symptom patterns, Colimex provides support that helps ease the overall symptom burden in contexts where the infectious agent has shown resistance to multiple other therapeutic options.”

Management of Chronic Respiratory Infection in Specific Patient Groups

Colimex is also relevant for individuals with underlying respiratory conditions, such as Cystic Fibrosis (CF). It is commonly used across conditions presenting with acute episodes and recurrent manifestations related to chronic colonization by resistant Pseudomonas aeruginosa in the lungs. The benefit is providing support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms and assists with maintaining functional stability during symptomatic periods.


Quick Fact Block

Property Description
Quick Fact: Relief for Systemic Stress Assists with managing symptoms related to systemic imbalance in critically ill patients.
Conditions Relevant to Use MDR infections like sepsis, bacteremia, and VAP.
Examples of Relevant Organisms Primarily Pseudomonas aeruginosa and Acinetobacter baumannii.
Patient Benefit Supports stability during periods of acute, severe symptomatic strain.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility and Non-Eligibility for Colimex

Official regulatory information strictly defines the populations who can and cannot use Colimex (a combination of dicyclomine and simethicone), primarily based on age and pre-existing medical conditions.

Contraindicated Populations

Use of Colimex is contraindicated (must not be used) in the following groups:

  • Infants under six months of age. This is a definitive age-related exclusion.
  • Individuals with a known hypersensitivity or allergy to dicyclomine, simethicone, or any component of the formulation.
  • Patients diagnosed with obstructive diseases of the gastrointestinal tract (e.g., pyloroduodenal stenosis) or urinary tract (e.g., obstructive uropathy).
  • Patients with glaucoma.
  • Patients with specific severe gastrointestinal conditions, including severe ulcerative colitis, toxic megacolon, or reflux esophagitis.

Restricted or Not Recommended Use

  • Pregnancy: Use is generally not recommended unless a physician determines the potential benefits outweigh the unknown risks to the fetus.
  • Breastfeeding Mothers: Use is not recommended as the active ingredient (dicyclomine) is known to be excreted into human breast milk and may affect the infant.

Use requires special consideration and caution in patients with conditions such as cardiac tachyarrhythmias, congestive heart failure, or hiatal hernia.

What should I know about interactions with other medicines?

Colimex's interaction profile, based on official regulatory documents, is structured around the risk of additive toxic effects and effects on nerve transmission.

Interaction Restrictions and Outcomes

Interaction Type Interacting Substance/Class Official Regulatory Statement
Co-Administration Restriction Sodium cephalothin Use of this combination should be avoided due to the formally documented risk of enhanced nephrotoxicity (kidney damage).
Additive Neuromuscular Effects Curariform Muscle Relaxants (e.g., Tubocurarine) Potentiate the neuromuscular blocking effect, requiring use with extreme caution.
Additive Neuromuscular Effects Aminoglycosides, Polymyxin B These agents interfere with nerve transmission; they should not be given except with the greatest caution.
Additive Nephrotoxicity Other Nephrotoxic Agents (General Class) Co-administration increases the risk of nephrotoxicity (additive toxicity), requiring caution and monitoring.

Population-Specific Interaction Notes

Official labels note that the possibility of apnea and neuromuscular blockade following administration is increased in patients with Impaired Renal Function or Advanced Age. This is because the medicine is primarily cleared through the kidneys, and reduced function in these populations can lead to heightened serum levels, intensifying the documented pharmacodynamic interactions.

Mechanism of Action

The mechanism integrates pharmacological modulation of the nervous system with physicochemical action within the gut.

Cholinergic Receptor Antagonism and Visceral Muscle Modulation

Dicyclomine acts as a competitive antagonist at specific muscarinic acetylcholine receptors ( M1, M2, and M3) located on the smooth muscle cells of the digestive tract. By blocking the binding of the neurotransmitter acetylcholine, the drug inhibits the nerve-signaled cascade that initiates muscle contraction. This action suppresses parasympathetic signaling to the gut, leading directly to a reduction in smooth muscle tone and a subsequent reduction in uncoordinated motility.

Physicochemical Anti-foaming Action and Pressure Modulation

Simethicone, a surface-active agent, functions non-pharmacologically by lowering the surface tension of the liquid film surrounding small, foamy gas bubbles trapped in the intestines. This physical change causes the tiny bubbles to destabilize and coalesce into larger pockets of free gas. This mechanism facilitates the clearance of intraluminal gas via normal physiological processes, which reduces gaseous distension.

Dosage and Administration Information

How Colimex is Used — Official Administration Guidelines

The use of Colimex is strictly governed by official protocols defining the delivery route, precise dosing unit, and patient-specific adjustments. The medicine is officially administered either Intravenously (IV) or Intramuscularly (IM) for systemic treatment, or through Inhalation for localized pulmonary infections.


Administration Routes and Dosing Regimens

Parameter Official Administration Principle
Routes IV/IM for systemic use; Inhalation for localized lung use.
Dosing Units Dosing is standardized using International Units (IU) or milligrams of Colistin Base Activity (CBA), requiring careful verification to prevent errors.
Frequency Systemic dosing is typically administered in 2 to 4 divided doses per day to maintain necessary concentration levels. Inhalation is generally twice daily.

Preparation and Specialized Use

The powder for injection must be handled carefully: it is reconstituted with sterile water by gently swirling, not shaking, to avoid frothing, and the final solution should be used promptly. A key regulatory requirement is the mandatory dose reduction for adult and pediatric patients with renal impairment, with specific dose tables provided based on measured Creatinine Clearance. Furthermore, IV administration can employ a continuous infusion technique, and the first inhaled dose requires administration under medical supervision. The duration of systemic use is dependent on the infection's resolution, while inhaled therapy for chronic conditions may continue long-term as warranted.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Colimex

Evidence for Use in Severe Multi-Drug Resistant Infections

Research on the use of Colistin (Colistimethate Sodium) for severe infections was studied for use against Multi-Drug Resistant (MDR) Gram-Negative Bacteria (GNB). This research examined critically ill adult patients in hospital settings, such as those with ventilator-associated pneumonia or bloodstream infections (sepsis). Due to the urgent and critical nature of these conditions, the evidence base is mainly made up of observational cohort studies, with a limited number of Randomized Controlled Trials (RCTs).

In these research settings, studies monitored outcomes related to systemic or functional imbalance, such as microbiological eradication (whether the infection was cleared from the bloodstream) and short-term survival (tracking mortality rates, typically at 30 days). The data describe measurements related to comparative use of Colistin with other antibiotics versus its use alone.

Evidence for Use in Chronic Respiratory Infection (Cystic Fibrosis)

Colistin was studied for its use as an inhaled medicine to manage the persistent bacterial colonization in the lungs of people with Cystic Fibrosis (CF), especially involving resistant Pseudomonas aeruginosa. Research examined the use in both pediatric and adult CF patients. These trials are often comparative studies that explore different forms of inhaled antibiotics over medium-term follow-up durations.

Studies explored how patients responded over defined time intervals, typically 6 to 12 months, in conditions presenting with cycles of stability and flare-ups. Key outcomes monitored included measures of lung function, such as FEV1, and the frequency of pulmonary exacerbations (outcomes capturing phases of heightened symptom activity).

Key Research Gaps and Remaining Uncertainties

Evidence quality varies across studies, and data are still emerging. For severe systemic infections, the evidence is often based on observational study designs rather than Randomized Controlled Trials (RCTs). Comparative evidence is lacking regarding the optimal use of Colistin alone or in combination with other antibiotics. Furthermore, long-term outcomes are not fully established, particularly concerning the development of bacterial resistance over extended periods.

Key Studies & References The role of Colistin in treating multidrug-resistant Gram-negative bacterial infections: systematic review and meta-analysis of observational studies

Frequently Asked Questions (FAQ)

Common questions about Colimex (FAQ)


Q: Is Colimex used for general stomach pain?

A: Official prescribing information indicates that Colimex is used for the treatment of spasmodic abdominal pain and general discomfort, such as cramping, associated with functional bowel disorders. The dicyclomine component is intended to relax the smooth muscles in the gut wall, which is associated with a reduction in painful contractions.


Q: Does Colimex require a prescription?

A: Official regulatory status indicates that Colimex, due to the presence of the antispasmodic Dicyclomine, is typically designated as a prescription-only medicine (POM). This means the drug is typically available by prescription and is designated for use under the guidance of a health professional.


Q: What is the difference between Colimex and an anti-acid medicine?

A: Colimex and anti-acids function in fundamentally different ways. Colimex is classified as an antispasmodic (to relax gut muscles) and an anti-foaming agent (to break up gas). This mechanism is distinct from anti-acid medicines, which chemically neutralize stomach acid.


Q: Why is Colimex sometimes described as an antispasmodic?

A: The medicine is described as an antispasmodic because its dicyclomine component acts to reduce the involuntary muscle contractions, or spasms, in the walls of the digestive tract. This action is the mechanism by which the drug is intended to manage cramping and pain.


Q: Does Colimex affect blood pressure?

A: Official warnings note that caution is advised when this medicine is used by individuals with certain cardiovascular conditions, including high blood pressure (hypertension) or certain heart rhythm disorders. This is due to the drug's potential to affect heart rate, and careful consideration by a health professional is generally required before use.


Q: Do studies support the use of Colimex for IBS symptoms?

A: Yes, the dicyclomine component of Colimex is specifically indicated for use as adjunctive therapy in the treatment of functional bowel disorders, also known as Irritable Bowel Syndrome (IBS). Its use is supported by studies that examine its effectiveness for IBS-related cramping.


Q: What if I forget to take a dose of Colimex?

A: If a dose is missed, official guidance typically recommends taking it as soon as the patient remembers. However, if it is already close to the time for the next scheduled dose, in which case official guidance generally states the missed dose is skipped.


Q: Can Colimex be used for gas or bloating relief?

A: Yes, Colimex contains Simethicone, which is an anti-foaming agent. This component is included in the formulation specifically to help relieve symptoms of excessive gas trapped in the intestines, such as bloating, pressure, and fullness.


Q: Why does the packaging list two main ingredients?

A: The product is a combination medicine containing two active ingredients, each with a different purpose. It includes Dicyclomine, which acts as an antispasmodic, and Simethicone, which acts as an anti-foaming agent for gas relief. The combination is intended to treat multiple symptoms simultaneously.


Q: Is Colimex the same as Dicyclomine?

A: No, Colimex is not the same as Dicyclomine alone. Dicyclomine is only one of the two active ingredients in the Colimex combination medicine, which also contains the anti-foaming agent Simethicone.


Q: What is the official dosage frequency described for Colimex?

A: Official administration guidelines for the active ingredients typically state that the medicine is administered in divided doses. The specific dosage frequency often involves taking the medicine up to four times daily, depending on the particular formulation and the prescribed amount.


Q: Why do official sources mention taking Colimex with food?

A: Official guidance on administration may suggest taking the medicine before or after meals. This is often recommended either to help minimize the potential for stomach discomfort or to align with a consistent treatment schedule, but this can vary by specific product.


Q: Does Colimex cause constipation?

A: Constipation is a commonly reported side effect noted in official regulatory documents. This effect is consistent with the drug's mechanism of reducing muscle movement in the gut.


Q: How quickly does Colimex usually start working?

A: Official pharmacological data indicates that the active component, Dicyclomine, is absorbed rapidly. The onset of effects is typically described as beginning within one to two hours, with the peak effects achieved within 60 to 90 minutes after the medicine is taken.


Q: What is the expected duration of the effects of Colimex?

A: The duration of the drug's effects is generally consistent with the typical dosing frequency described in regulatory information. Prescribing schedules often recommend taking the medicine up to four times daily, which is often reflective of the duration of a single dose.


Q: Can Colimex be taken long-term?

A: Long-term use is not typically addressed in general product information, as the drug is commonly used for episodic symptom management. The duration of use is determined by a health professional based on the specific condition being managed.


Q: Are there any official warnings about driving while using Colimex?

A: Yes, regulatory labeling includes an official warning that the drug may cause side effects such as drowsiness or blurred vision. Patients are cautioned in official labeling about engaging in activities such as operating a motor vehicle or other heavy machinery until they know how the medicine affects them.


Q: Can Colimex be taken by people with stomach ulcers?

A: The medicine is strictly contraindicated in several severe gastrointestinal conditions, such as severe ulcerative colitis. Caution is required for use in other GI disorders, and suitability requires review by a health professional.


Q: What happens if I take Colimex with alcohol?

A: Official sources typically state that patients should not consume alcohol while using this medicine. The combination may intensify central nervous system side effects, leading to excessive drowsiness and dizziness.


Q: Can people with glaucoma take Colimex?

A: No, Colimex is explicitly contraindicated and should not be used in patients diagnosed with glaucoma. This restriction is noted in regulatory documents due to the risk of worsening the patient’s condition.


Q: Why are people with certain prostate conditions advised caution with Colimex?

A: Caution is specifically advised for individuals with known or suspected prostatic enlargement (prostatic hypertrophy). Regulatory information notes this precaution because the drug carries a risk of potentially causing or worsening urinary retention (difficulty passing urine).


Q: Can Colimex affect vision or cause blurred sight?

A: Yes, blurred vision is an officially listed and commonly reported adverse reaction. If a patient experiences vision changes, this is a symptom that patients are advised to report to their health professional.


Q: Does Colimex interfere with thyroid medication?

A: Yes, the simethicone component of Colimex may interfere with the body's ability to absorb certain thyroid medications, such as levothyroxine. To prevent this potential interaction, a time separation between the two medicines is often suggested in administration guidelines.

How should Colimex be stored and disposed of?

Official Storage and Disposal Requirements

Colistimethate Sodium (Colimex) must be stored according to regulatory labeling to ensure stability. The dry powder for solution requires storage at controlled room temperature (20 C to 25 C) and must be protected from light and excessive moisture. The medicine must be kept in its original container until use.

Once the powder is mixed, the reconstituted solution has a limited stability period and often requires refrigerated storage (2 C to 8 C) for a short duration before disposal. Any solution showing haziness or precipitate must be discarded immediately. The medicine must be stored out of the sight and reach of children.

For disposal, do not throw away unused or expired medicine in household trash or wastewater. Consult a pharmacist or follow local waste disposal instructions for pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colimex found in:

A-Z Index: